Vaccine Resources

Flu Information

A Message from IEHP Medical Director, Dr. Takashi Wada

The 2022-2023 influenza season continues to coincide with circulation of COVID-19 virus (SARS-CoV-2). As of August 2022, approximately 94.2 million cases of COVID-19 had been reported in the United States. Influenza vaccination remains an important tool for the prevention of potentially severe respiratory illness, which helps decrease the stress on the U.S. health care system. IEHP DualChoice members who are 18 years of age or older may obtain flu vaccines through the IEHP Pharmacy Vaccine Network.

Frequently Asked Influenza (Flu) Questions: 2022-2023 Season

What’s New for 2022-2023

 

 By clicking on these links, you will be leaving the IEHP website.

  • The composition of flu vaccines has been updated.
  • For the 2022-2023 flu season, there are three flu vaccines that are preferentially recommended for people 65 years and older. These are Fluzone High-Dose Quadrivalent vaccineFlublok Quadrivalent recombinant  flu vaccine and Fluad Quadrivalent adjuvanted flu vaccine.
  • The recommended timing of vaccination is similar to last season. For most people who need only one dose for the season, September and October are generally good times to get vaccinated. Vaccination in July and August is not recommended for most adults but can be considered for some groups. While ideally it’s recommended to get vaccinated by the end of October, it’s important to know that vaccination after October can still provide protection during the peak of flu season.
  • The age indication for the cell culture-based inactivated flu vaccine, Flucelvax Quadrivalent (ccIIV4), changed from 2 years and older to 6 months and older.
  • Pre-filled Afluria Quadrivalent flu shots for children are not expected to be available this season. However, children can receive this vaccine from a multidose vial at the recommended dose.

Mpox Information

Mpox Vaccination Locations

 

Please advise members to call before going in for a vaccination as some locations are only available with appointments. Members may make appointments for the JYNNEOS vaccine at https://myturn.ca.gov/.

 

Mpox Testing

 

As of December 8, 2022, no commercial testing is available for the diagnosis of Mpox. Providers may contact CDC in the diagnosis, management of patients with suspected Mpox, and for any additional information regarding Mpox connect with the CDC Emergency Operations Center.

  • Phone: 1-770-488-7100, Monday through Friday, 8:00 AM to 4:30 PM EST
  • After Hours Phone: 1-404-639-2888

 

Treatment

 

Mpox patients usually recover fully within 2-4 weeks without the need for medical treatment. While there are no treatments specifically for Mpox, the virus that causes Mpox is similar to the smallpox virus and therefore antiviral drugs developed to protect against smallpox may be used. The antiviral drug, tecovirimat (TPOXX), has been approved by the FDA to treat smallpox in adults and children.

 

If you prescribe tecovirimat to treat members with Mpox the member must sign a consent form stating tecovirimat is an investigational drug that has not yet been approved by the FDA for treatment of Mpox.

More information about tecovirimat visit

Preventive Services Information

Immunizations

By clicking on these links, you will be leaving the IEHP website.

CDC ACIP Vaccine Recommendations and Guidelines:
CDC ACIP Immunization Schedule for Children:
CDC ACIP Immunization Schedule for Adults:
California Immunization Registry Portal (CAIR):
 
You will need Adobe Acrobat Reader 6.0 or later to view the PDF files. You can download a free copy by clicking here.